Medicine
Volume 36, Issue 2 , Pages 82-87 , February 2008

Breathlessness in advanced disease

References 

  1. Claessens MT, Lynn J, Zhong Z, et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. Study to understand prognoses and preferences for outcomes and risks of treatments. J Am Geriatr Soc. 2000;48(suppl 5):S146–S153
  2. Edmonds P, Karlsen S, Khan S, Addington-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliat Med. 2001;15:287–295
  3. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage. 2001;21:95–102
  4. Gillette MA, Schwartzstein RM. Mechanisms of dyspnoea. In:  Ahmedzai SH,  Muers M editor. Supportive care in respiratory disease. Oxford: OUP; 2005;
  5. Parsons LM, Egan G, Liotti M, et al. Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air. Proc Natl Acad Sci U S A. 2001;4:2041–2046
  6. Clemens KE, Klaschik E. Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage. 2007;33:473–481
  7. Rock LLK, Schwartzstein RM. Mechanisms of dyspnea in chronic lung disease. Curr Opin Support Palliat Care. 2007;1:102–108
  8. Vora VA, Ahmedzai SH. Pulse oximetry in supportive and palliative care. Support Care Cancer. 2004;12:758–761
  9. Hoskin P, Ahmedzai SH. Assessment and management of respiratory symptoms of malignant disease. In:  Ahmedzai SH,  Muers M editor. Supportive care in respiratory disease. Oxford: OUP; 2005;
  10. Booth S, Anderson H, Swannick M, et al. The use of oxygen in the palliation of breathlessness. Resp Med. 2004;98:66–77
  11. Ahmedzai SH, Laude E, Robertson A, Troy G, Vora V. A double-blind, randomised, controlled Phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer. 2004;90:366–371
  12. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis. 1987;136:58–61
  13. Thomas JR, von Gunten CF. Clinical management of dyspnoea. Lancet Oncology. 2002;3:223–228
  14. Jennings A-L, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939–944
  15. Abernethy AP, Currow DC, Frith P, Fazekas BS. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327:523–528
  16. Poole PJ, Vele AG, Black PN. The efect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1877–1880
  17. Shimoyama N, Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage. 2002;23:73–76
  18. Navigante AH, Cerchietti LCA, Castro MA, Lutteral MA, Cabalar ME. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnoea perception in patients with advanced cancer. J Pain Symptom Manage. 2006;31:38–47
  19. Schneerson J. Neuromuscular and skeletal diseases. In:  Ahmedzai SH,  Muers M editor. Supportive care in respiratory disease. Oxford: OUP; 2005;
  20. MacLeod R. Psychosocial therapies. In:  Ahmedzai SH,  Muers M editor. Supportive care in respiratory disease. Oxford: OUP; 2005;

PII: S1357-3039(07)00430-6

doi: 10.1016/j.mpmed.2007.12.010

Medicine
Volume 36, Issue 2 , Pages 82-87 , February 2008

Article Tools